Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04597502 · ClinicalTrials.gov registry record · NA
The Effects of Terminalia Chebula Fruit Extract on the Gut Microbiome and Skin Biophysical Properties
A NA study of Human Microbiome, sponsored by Integrative Skin Science and Research.
- Completed
- Registry status
- NA
- Development phase
- 58
- Enrollment target
- 1
- Study location
NCT04597502: Completed NA study of Human Microbiome, sponsored by Integrative Skin Science and Research.
NCT04597502 is a NA study of Human Microbiome that has completed, run by Integrative Skin Science and Research. The registered enrollment target is 58 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04597502, a NA study of Human Microbiome, has completed, sponsored by Integrative Skin Science and Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 58 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the use of oral Terminalia chebula fruit extract on the gut microbiome and skin biophysical properties. The fruit is commonly used for skin treatments in India. It is thought to have antioxidant properties, reduce inflammation and affect the microorganisms in the gut. The information the investigators will learn from this study may indicate how and if oral dosing can affect the skin and gut microbiome. This may lead to an improved understanding of the skin and determine whether these oral products are effective for improving the skin's appearance.
Primary Outcome
Stool is collected and analyzed for species of bacteria through nucleic acid sequencing.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Terminalia Chebula fruit extract
- OTHER Topical Terminalia Chebula
- OTHER Topical Placebo
Study Locations (1)
California
- Integrative Skin Science and Research - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2020-10-15 |
| Est. Completion | 2022-09-01 |
| Phase | NA |
What the finished NCT04597502 record still lists
NCT04597502 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Human Microbiome appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT04597502 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04597502 about?
NCT04597502 is a clinical study titled "The Effects of Terminalia Chebula Fruit Extract on the Gut Microbiome and Skin Biophysical Properties". The purpose of this study is to assess the use of oral Terminalia chebula fruit extract on the gut microbiome and skin biophysical properties. The fruit is commonly used for skin treatments in India. It is thought to have antioxidant properties, reduce inflammation and affect the microorganisms in t...
What is the current status of trial NCT04597502?
This trial is currently completed. It is a NA study. The enrollment target is 58 participants. The study started on 2020-10-15. Estimated completion is 2022-09-01.
What conditions does trial NCT04597502 study?
This clinical trial studies the following conditions: Human Microbiome.
What interventions are being tested in trial NCT04597502?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Terminalia Chebula fruit extract (DIETARY_SUPPLEMENT), Topical Terminalia Chebula (OTHER), Topical Placebo (OTHER).
Who is sponsoring clinical trial NCT04597502?
This trial is sponsored by Integrative Skin Science and Research, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04597502 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Microbiome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04597502's enrollment target sits among peer trials
58 1256th of 2000 higher than 740 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI